Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

211.96 -6.08 (-2.79%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop
ONEOK’s 6% Dividend Draws Smart Money Despite a Nearly 30% Drop 
Via The Motley Fool
Topics Energy Regulatory Compliance
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally
Why Some Investors Are Taking Profits on JPMorgan After Its Big Rally 
Via The Motley Fool
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth 
Via The Motley Fool
Topics Regulatory Compliance
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat
Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock
Bullish Bet: Investment Manager Makes Strategic Buy of Prologis Stock 
Via The Motley Fool
Topics Economy Regulatory Compliance
Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing
Blue Owl Capital Stock Trimmed by Investment Manager, According to Recent Filing 
Via The Motley Fool
Topics Regulatory Compliance
Investment Manager Doubles Down on Regional Bank Stock, According to Recent Filing
Investment Manager Doubles Down on Regional Bank Stock, According to Recent Filing 
Via The Motley Fool
Topics Credit Cards Regulatory Compliance
Motley Fool Co-Founder Tom Gardner: The Quarterly Call
In our second Quarterly Call, Motley Fool CEO and co-founder Tom Gardner talked about the current market and what to do about it. Tom also shared five investment ideas. 
Via The Motley Fool
Topics Artificial Intelligence
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector
Could AbbVie be the next big opportunity for investors? Tune in as our experts dissect the company's performance and future potential. 
Via The Motley Fool
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades'
Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Stephanie Link picks Aptiv (APTV). Joe Terranova chooses Palo Alto Networks... 
Via Benzinga
This Florida Fund Is Betting $21 Million on Vertiv as AI Data Center Growth Accelerates
This Florida Fund Is Betting $21 Million on Vertiv as AI Data Center Growth Accelerates 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
Abacus FCF Advisors Bets $16 Million on Hilton Even as Hotel Stock Lags Market
Abacus FCF Advisors Bets $16 Million on Hilton Even as Hotel Stock Lags Market 
Via The Motley Fool
Topics Regulatory Compliance
Why This Florida Fund Locked In DoorDash Gains After a 70% Stock Surge
Via The Motley Fool
Topics Regulatory Compliance
Florida Fund Takes $17 Million Stake in Tapestry Amid Luxury Retail Stock's Big Rally
Via The Motley Fool
Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic
Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs. 
Via Stocktwits
Topics Government
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
Via The Motley Fool
3 Top Dividend Growth Stocks to Buy Right Now
These dividend growth stocks merit serious consideration. 
Via The Motley Fool
Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades'
Analysts discuss stock performance and potential of AbbVie Inc, Amazon, Sixth Street Specialty Lending, and Datadog. Check out premarket coverage. 
Via Benzinga
2 Profitable Stocks to Research Further and 1 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
VIX Roars Back: Trade Tensions Ignite "Fear Gauge," Signaling Potential Market Shift
The financial markets were gripped by a sudden wave of apprehension this past week as the Cboe Volatility Index (VIX), often dubbed the "fear gauge," experienced its most significant single-day surge... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug
In the second quarter, Rinvoq was the second most revenue-generating drug from AbbVie’s portfolio after Skyrizi. 
Via Stocktwits
2 Dividend Stocks to Double Up on Right Now
These two companies can help you sleep easy at night. 
Via The Motley Fool
Topics Economy Intellectual Property World Trade
iShares CUD: Navigating the Nuances of Dividend Growth in a Dynamic Market
As the closing bell rings on October 10, 2025, the iShares US Dividend Growers Index ETF (CAD-Hedged) (TSX: CUD) stands as a crucial barometer for Canadian income investors seeking exposure to... 
Via MarketMinute
Topics Bonds ETFs Economy
JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance
JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the... 
Via MarketMinute
Topics Economy Intellectual Property
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
Carolina Wealth Trims It's AbbVie Stake to Nearly Nothing
Via The Motley Fool
Topics Government World Trade
A Congress Member Sold Up To $300K In A.O. Smith Stock: Here's What You Need To Know
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.